These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
146 related items for PubMed ID: 9622100
1. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Couderc B, Zitvogel L, Douin-Echinard V, Djennane L, Tahara H, Favre G, Lotze MT, Robbins PD. Cancer Gene Ther; 1998; 5(3):163-75. PubMed ID: 9622100 [Abstract] [Full Text] [Related]
2. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, Favre G, Couderc B. Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533 [Abstract] [Full Text] [Related]
3. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells. Grangeon C, Cormary C, Douin-Echinard V, Favre G, Couderc B, Tilkin-Mariamé AF. Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445 [Abstract] [Full Text] [Related]
4. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity. Cormary C, Hiver E, Mariamé B, Favre G, Tilkin-Mariamé AF. Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983 [Abstract] [Full Text] [Related]
5. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules. Cormary C, Gonzalez R, Faye JC, Favre G, Tilkin-Mariamé AF. Cancer Gene Ther; 2004 Jul; 11(7):497-507. PubMed ID: 15153937 [Abstract] [Full Text] [Related]
6. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. Hintzen RQ, Lens SM, Lammers K, Kuiper H, Beckmann MP, van Lier RA. J Immunol; 1995 Mar 15; 154(6):2612-23. PubMed ID: 7876536 [Abstract] [Full Text] [Related]
9. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. Akiba H, Oshima H, Takeda K, Atsuta M, Nakano H, Nakajima A, Nohara C, Yagita H, Okumura K. J Immunol; 1999 Jun 15; 162(12):7058-66. PubMed ID: 10358148 [Abstract] [Full Text] [Related]
14. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40. Ruybal P, Gravisaco MJ, Barcala V, Escalada A, Di Sciullo P, Waldner C, Mongini C. Vaccine; 2008 Jan 30; 26(5):697-705. PubMed ID: 18155328 [Abstract] [Full Text] [Related]
16. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. Loskog A, Tötterman TH, Böhle A, Brandau S. Cancer Gene Ther; 2002 Oct 30; 9(10):846-53. PubMed ID: 12224026 [Abstract] [Full Text] [Related]
17. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz JB, Ohgaki H, Aguzzi A, Rammensee HG, Weller M. Cancer Res; 2002 May 01; 62(9):2592-9. PubMed ID: 11980654 [Abstract] [Full Text] [Related]
18. Characterization of murine CD70, the ligand of the TNF receptor family member CD27. Tesselaar K, Gravestein LA, van Schijndel GM, Borst J, van Lier RA. J Immunol; 1997 Nov 15; 159(10):4959-65. PubMed ID: 9366422 [Abstract] [Full Text] [Related]
19. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. Borges L, Miller RE, Jones J, Ariail K, Whitmore J, Fanslow W, Lynch DH. J Immunol; 1999 Aug 01; 163(3):1289-97. PubMed ID: 10415026 [Abstract] [Full Text] [Related]